Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. has demonstrated a robust financial position with cash and investments increasing to $16.6 million, supported by CPRIT advances and market activities, alongside compliance with Nasdaq listing standards. The company's CNSide Diagnostic platform is showing promising commercial readiness, with expected revenue growth from approximately $1 million in 2025 to $38 million by 2032, fueled by expanding licensing and user adoption in new states. Positive preliminary results from the ReSPECT-LM study highlight a 76% radiographic response rate and a promising mean overall survival of 9 months, suggesting strong potential for future product advancements in CNS cancer treatment.

Bears say

Plus Therapeutics Inc. reported a total operating loss of $4.5 million and a net loss of $4.4 million, indicating significant financial challenges. The company’s reliance on grant revenue, which stood at only $1.4 million, raises concerns about its ability to sustain operations without additional funding. Furthermore, the dilution from the recent equity raise has contributed to a downward adjustment in the price target, reflecting investor apprehension regarding the company's financial stability and future prospects.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Nov 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.